The Role of Systemic Immuno-inflammatory Factors in Resectable Pancreatic Adenocarcinoma

CompletedOBSERVATIONAL
Enrollment

312

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

August 1, 2021

Study Completion Date

August 1, 2021

Conditions
Pancreas Cancer, Duct Cell Adenocarcinoma
Interventions
OTHER

Systemic immune-inflammatory markers

Systemic immune-inflammatory markers used in this study: total neutrophil count, total lymphocyte count, total monocyte count, total platelet count, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), prognostic nutritional index (PNI)

Trial Locations (1)

400495

"Regional Institute of Gastroenterology and Hepatology Prof. Dr. O. Fodor", Cluj-Napoca

All Listed Sponsors
collaborator

Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor

OTHER

lead

Iuliu Hatieganu University of Medicine and Pharmacy

OTHER

NCT05025371 - The Role of Systemic Immuno-inflammatory Factors in Resectable Pancreatic Adenocarcinoma | Biotech Hunter | Biotech Hunter